[
  {
    "ts": null,
    "headline": "2 Cash-Producing Stocks with Exciting Potential and 1 We Ignore",
    "summary": "While strong cash flow is a key indicator of stability, it doesn’t always translate to superior returns. Some cash-heavy businesses struggle with inefficient spending, slowing demand, or weak competitive positioning.",
    "url": "https://finnhub.io/api/news?id=10044eb56e5bac105636b96a9d8beaff526555f515821f6fdfc9c86d42fc33ab",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1755664626,
      "headline": "2 Cash-Producing Stocks with Exciting Potential and 1 We Ignore",
      "id": 136438058,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "BIIB",
      "source": "Yahoo",
      "summary": "While strong cash flow is a key indicator of stability, it doesn’t always translate to superior returns. Some cash-heavy businesses struggle with inefficient spending, slowing demand, or weak competitive positioning.",
      "url": "https://finnhub.io/api/news?id=10044eb56e5bac105636b96a9d8beaff526555f515821f6fdfc9c86d42fc33ab"
    }
  },
  {
    "ts": null,
    "headline": "Alzheimer's Disease: When All Else Fails",
    "summary": "Most candidates fail to show meaningful clinical benefit in Alzheimer's. Read why I am against investing in companies based solely on their Alzheimer's drug programs.",
    "url": "https://finnhub.io/api/news?id=de7cc61f7b72090da27c6cd7ed9b7dc24254cb04a039676a0ff2530bb367244a",
    "source": "SeekingAlpha",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1755651552,
      "headline": "Alzheimer's Disease: When All Else Fails",
      "id": 136434145,
      "image": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1405486469/image_1405486469.jpg?io=getty-c-w1536",
      "related": "BIIB",
      "source": "SeekingAlpha",
      "summary": "Most candidates fail to show meaningful clinical benefit in Alzheimer's. Read why I am against investing in companies based solely on their Alzheimer's drug programs.",
      "url": "https://finnhub.io/api/news?id=de7cc61f7b72090da27c6cd7ed9b7dc24254cb04a039676a0ff2530bb367244a"
    }
  }
]